Complement cascade and kidney transplantation: The rediscovery of an ancient enemy

Area of Science:

• Nephrology
• Immunology
• Transplant Medicine

Background:

• Complement activity identification is crucial in nephropathology.
• The complement cascade's role in glomerular disease is established, but treatment options were limited.
• Targeted therapies since 2006 have redefined the complement pathway's therapeutic potential in renal disease.

Purpose of the Study:

• To review the significance of the complement cascade in renal transplantation diseases.
• To focus on current and potential complement-inhibiting treatments.
• To identify future strategies for complement inhibition in renal disease.

Main Methods:

• Literature review of experimental models and molecular studies.
• Analysis of complement cascade's role in various renal conditions.
• Evaluation of existing and investigational complement-targeting drugs.

Main Results:

• The complement cascade is implicated in ischemia-reperfusion injury, C3 glomerulopathy, rejection, and atypical hemolytic uremic syndrome in renal grafts.
• Eculizumab, a complement-targeting drug, is approved for atypical hemolytic uremic syndrome and under investigation for other renal conditions.
• Complement inhibition represents a promising therapeutic frontier in renal transplantation.

Conclusions:

• Complement cascade activation contributes significantly to renal graft damage.
• Targeted complement inhibition offers a novel therapeutic strategy for renal transplantation complications.
• Further research into complement inhibition is warranted for various kidney diseases.